Ticagrelor and prasugrel have similar rates of myocardial infarction (MI) and death at 1 year after percutaneous coronary intervention (PCI) for either acute coronary syndrome (ACS) or chronic coronary syndrome (CCS), according to a real-world analysis of data from a single center.